INVEGA TRINZA® Common Dosing and Administration Topics



Consistent with the Prescribing Information for INVEGA TRINZA® and INVEGA SUSTENNA®:

  • INVEGA TRINZA® is to be used only after INVEGA SUSTENNA® has been established as adequate treatment for at least four months.
  • For switching from INVEGA TRINZA® to INVEGA SUSTENNA®, INVEGA SUSTENNA® should be started 3 months after the last INVEGA TRINZA® dose, using the equivalent 3.5-fold lower dose as shown in the table below.

    If the Last Dose of INVEGA TRINZA® is: Initiate* INVEGA SUSTENNA® 3 Months Later at the Following Dose:
    273 mg 78 mg
    410 mg 117 mg
    546 mg 156 mg
    819 mg 234 mg
    * The initiation dosing as described in the prescribing information for INVEGA SUSTENNA® is not required.

  • INVEGA SUSTENNA® should then continue, dosed at monthly intervals.
  • Administration: For intramuscular injection only by a healthcare professional. Care should be taken to avoid inadvertent injection into a blood vessel.

For illustrative displays of this dosing scenario, please click the links below.

Educational Dose Illustrator for:
INVEGA SUSTENNA® (paliperidone palmitate)
INVEGA TRINZA® (paliperidone palmitate)

The Educational Dose Illustrator can be used to visualize how dosing affects paliperidone plasma concentrations following administration of:


  • the treatment of schizophrenia in adults
  • the treatment of schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants


  • the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® for at least four months.

This resource simulates the paliperidone plasma concentrations over time resulting from different dosing scenarios that are set forth in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. The Educational Dose Illustrator is intended to be used as a resource to foster a better understanding of, and educate healthcare professionals about, the dosing recommendations provided in the respective Prescribing Information for INVEGA SUSTENNA® and INVEGA TRINZA®. It is intended for educational purposes only.

Because the simulated patient paliperidone plasma levels shown in the dosing scenarios are based upon aggregated pharmacokinetic information from clinical studies, the simulations may not be representative of individual patient response.

Please Acknowledge

The information contained in this web site is intended for US healthcare professionals only. Privacy Policy.

Please Confirm


Thank you for visiting the Educational Dose Illustrator.

By clicking "Continue" below, you will be taken to a website where our Privacy Policy does not apply. You are solely responsible for your interactions with such websites.

We encourage you to read the Privacy Policy of every website you visit. Please view our Privacy Policy at your convenience.

Continue Cancel